Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Am J Respir Crit Care Med ; 156(3 Pt 1): 855-61, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9310004

ABSTRACT

The hypothesis that the in vivo function of Survanta (Beractant) can be improved by supplementation with synthetic surfactant peptides B and C was tested in a surfactant-deficient rat model. Full length surfactant protein-B (SP-B1-78) (B) and palmitoylated surfactant protein-C (SP-C1-35) (C), and synthetic KL4 peptide were added to Survanta after extraction, creating extracted Survanta (ES) with 1% B, 2% B, and 2% B plus 1% C, or mixed with Survanta without extraction, creating modified Survanta (S) with 2% B, 2% B plus 1% C, and 2% KL4. Adult rats were ventilated with 100% oxygen, tidal volumes (VT) of 7.5 ml/kg and a rate of 60/min, and were lavaged until the PaO2 dropped below 80 mm Hg, when 100 mg/kg of surfactant was instilled. After 15 to 60 min of ventilation, pressure-volume (P-V) curves were generated in situ. Instillation of ES or S with 2% B plus 1% C led to the greatest increase in oxygenation, closely followed by ES and S with 2% B, and more distantly by S plus 2% KL4. TLC was comparable among the ES and S groups, but greater than that of air-placebo controls. These data suggest that spiking of Survanta with synthetic SP-B and SP-C increased oxygenation more effectively than B or KL4 alone in this surfactant-deficient rat model.


Subject(s)
Biological Products , Hyaline Membrane Disease/drug therapy , Oxygen/blood , Proteolipids/therapeutic use , Pulmonary Surfactants/therapeutic use , Amino Acid Sequence , Animals , Blood Gas Analysis , Disease Models, Animal , Drug Combinations , Drug Evaluation, Preclinical , Humans , Hyaline Membrane Disease/metabolism , Infant, Newborn , Instillation, Drug , Male , Molecular Sequence Data , Proteolipids/chemistry , Pulmonary Surfactants/chemistry , Rats , Rats, Sprague-Dawley
2.
Pediatr Res ; 41(4 Pt 1): 457-63, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9098845

ABSTRACT

To determine the effects of inhaled NO (iNO) on pulmonary edema and lung inflammation in experimental hyaline membrane disease (HMD), we measured the effects of iNO on pulmonary hemodynamics, gas exchange, pulmonary edema, and lung myeloperoxidase (MPO) activity in extremely premature lambs (115 d of gestation, 0.78 term). In protocol 1, we measured the effects of iNO (20 ppm) on lung vascular endothelial permeability to 125I-labeled albumin (indexed to blood volume using 57Cr-tagged red blood cells) during 1 h (n = 10) and 3 h (n = 14) of conventional mechanical ventilation with FiO2 = 1.00. In comparison with controls, iNO improved pulmonary hemodynamics and gas exchange, but did not alter lung weight-to-dry weight ratio or vascular permeability to albumin after 1 or 3 h of mechanical ventilation. To determine whether low dose iNO (5 ppm) would decrease lung neutrophil accumulation in severe HMD, we measured lung MPO activity after 4 h of mechanical ventilation with or without iNO (protocol 2). Low dose iNO improved gas exchange during 4 h of mechanical ventilation (PaO2 at 4 h: 119 +/- 35 mm Hg iNO versus 41 +/- 7 mm Hg control, p < 0.05), and reduced MPO activity by 79% (p < 0.05). We conclude that low dose iNO increases pulmonary blood flow, without worsening pulmonary edema, and decreases lung neutrophil accumulation in severe experimental HMD. We speculate that in addition to its hemodynamic effects, low dose iNO decreases early neutrophil recruitment and may attenuate lung injury in severe HMD.


Subject(s)
Capillary Permeability/drug effects , Hyaline Membrane Disease/drug therapy , Lung/blood supply , Neutrophils/drug effects , Nitric Oxide/pharmacology , Pulmonary Edema/drug therapy , Administration, Inhalation , Animals , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Hemodynamics/drug effects , Humans , Hyaline Membrane Disease/blood , Hyaline Membrane Disease/etiology , Infant, Newborn , Leukocyte Count , Pulmonary Gas Exchange/drug effects , Respiration, Artificial , Sheep
3.
Acta Paediatr ; 86(12): 1370-3, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9475318

ABSTRACT

Chronic lung disease is associated with several poorly defined risk factors for impaired cerebral development. Late neonatal onset of subependymal hyperechogenic areas in the caudothalamic groove has been reported in association with dexamethasone treatment and postnatal cytomegalovirus infection. We reviewed charts of 18 patients who developed subependymal hyperechogenicity beyond the first week of life, as well as charts of 79 patients belonging to a prospective surfactant study group. Thirteen of the 18 patients with subependymal hyperdensities had been treated with surfactant and were all found in the subgroup with chronic lung disease. In the surfactant-treated patients who did not develop chronic lung disease, we could not find any patient with subependymal hyperdensities. From the remaining five patients with ultrasound lesions, but who were not treated with surfactant, three had developed chronic lung disease. There was no evident association with dexamethasone treatment or cytomegalovirus infection. Our results support the idea of an association between chronic lung disease and the described echographic lesions in the caudothalamic groove, but the nature of the link between them is still unclear.


Subject(s)
Bronchopulmonary Dysplasia/complications , Cerebral Hemorrhage/diagnostic imaging , Cytomegalovirus Infections/complications , Ependyma/diagnostic imaging , Infant, Premature , Thalamus/diagnostic imaging , Betamethasone/administration & dosage , Betamethasone/adverse effects , Bronchopulmonary Dysplasia/drug therapy , Bronchopulmonary Dysplasia/mortality , Cerebral Hemorrhage/etiology , Cerebral Hemorrhage/mortality , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/mortality , Ependyma/pathology , Female , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Hyaline Membrane Disease/complications , Hyaline Membrane Disease/drug therapy , Hyaline Membrane Disease/mortality , Infant, Newborn , Male , Retrospective Studies , Survival Rate , Thalamus/pathology , Ultrasonography
4.
Am J Dis Child ; 144(8): 915-9, 1990 Aug.
Article in English | MEDLINE | ID: mdl-2378340

ABSTRACT

We hypothesized that administration of the iron chelator deferoxamine would inhibit iron-catalyzed free radical generation and lessen the severity of oxygen-induced pulmonary injury. To evaluate its efficacy and safety in premature infants, we administered deferoxamine by intravenous infusion to five premature baboons with hyaline membrane disease supported with conventional ventilation and 100% oxygen for 6 days. Seven animals served as controls. Deferoxamine treatment was initiated at 10 mg/kg per hour but, after the precipitous death of the first animal, was progressively reduced to 1.25 mg/kg per hour in the other animals. Four of five deferoxamine-treated baboons developed cardiovascular collapse and all five died by 42 hours. Five of the seven control animals survived the 6-day experimental period. Since cardiovascular toxic effects have not previously been reported, these findings suggest unique vulnerability of the immature cardiovascular system to iron chelation.


Subject(s)
Cardiovascular Diseases/chemically induced , Deferoxamine/adverse effects , Hyaline Membrane Disease/drug therapy , Animals , Deferoxamine/administration & dosage , Deferoxamine/therapeutic use , Drug Evaluation, Preclinical , Female , Humans , Hyaline Membrane Disease/mortality , Hyaline Membrane Disease/therapy , Infant, Newborn , Infusions, Intravenous , Male , Papio , Respiration, Artificial
5.
Respiration ; 45(4): 327-38, 1984.
Article in English | MEDLINE | ID: mdl-6566397

ABSTRACT

This paper presents a sequence of tests for experimental evaluation of potential substitutes for pulmonary surfactant. Differential thermal analysis and the pulsating bubble technique were applied to identify an emulsified mixture of synthetic lipids with properties similar to those of natural surfactant. Instilled into the airways of premature newborn rabbits, this emulsion improved pulmonary pressure-volume characteristics and enhanced lung-thorax compliance during artificial ventilation. However, the in vivo effect was inferior to that of natural surfactant, especially as the emulsion failed to prevent the development of bronchiolar epithelial lesions.


Subject(s)
Hyaline Membrane Disease/drug therapy , Lipids/administration & dosage , Lung/physiopathology , Animals , Animals, Newborn , Cholesterol/administration & dosage , Drug Evaluation, Preclinical , Emulsions , Follow-Up Studies , Humans , In Vitro Techniques , Infant, Newborn , Lung/pathology , Lung Compliance , Lysophosphatidylcholines/administration & dosage , Oils/administration & dosage , Phosphatidylglycerols/administration & dosage , Pulmonary Surfactants/administration & dosage , Rabbits , Glycine max , Surface Properties
SELECTION OF CITATIONS
SEARCH DETAIL